Cord blood transplantation (CBT) has been shown to be a valuable alternative to SCT. As HLA-mismatched transplantation, including CBT, has increased, allosensitization has become a more significant problem. Sensitization to HLA Ags increases the risk of graft failure and frequently causes patients to be excluded as candidates for transplantation, particularly for CBT.
1,2 Although a substantial amount of evidence regarding solid organ transplantation for highly sensitized patients has been accumulated, 3 SCT for such patients has not been well evaluated. To our knowledge, HLA-mismatched CBT from an unrelated donor for patients with allosensitization has not been addressed to date. Here, we report two cases of successful engraftment after HLA-mismatched CBT for patients with anti-HLA Abs by identifying acceptable HLA Ag mismatches through Luminex technology and flow cytometry cross-match tests, as used in kidney transplantation. 4 Although the following two cases needed SCT, they could not use donor sources other than HLA-mismatched unrelated cord blood grafts for transplantation. They, however, had plt transfusion refractoriness due to anti-HLA Abs. To reduce the risk of graft failure owing to alloimmunization, we identified the HLA Ags reactive to their anti-HLA Abs using Luminex technology (LABScreen, One Lambda, Canoga Park, CA, USA), selected the cord blood graft without those Ags and confirmed the absence of cross-reactivity by flow cytometry cross-match tests. Luminex technology uses microbeads coated with class I or class II HLA Ags and a flow analyzer. When appropriate, a single-Ag assay allows confirmation of Ab specificity.
5 Table 1 shows the anti-HLA Abs identified, and the HLA of the donors and the recipients in both cases.
Patient 1
A 49-year-old Japanese woman with AML (FAB: M1) in second CR received HLA-matched BMT from an unrelated donor from the Buddhist Tzu Chi Stem Cells Center registry. The preparative regimen consisted of TBI 12 Gy in six fractions from day À7 to À5 and CY 60 mg/kg once daily i.v. on day À4 and À3 (total dose 120 mg/kg). She received an infusion of unrelated bone marrow containing 0.8 Â 10 8 nucleated cells per kg. CsA and short-term MTX were administered for GVHD prophylaxis. As the bone marrow examination on day 23 revealed markedly hypocellular bone marrow, G-CSF was started. However, peripheral cytopenia persisted, and graft rejection was diagnosed based on severe bone marrow hypoplasia and almost complete host chimerism of PBMC on day 30. She had no available donor other than a serologically two HLA Ag-mismatched cord blood graft. Although she had plt transfusion refractoriness due to anti-HLA Abs since she received the consolidation therapy for AML in first CR 3 years before, we decided to perform CBT using the methods described above. She received a reduced-intensity conditioning regimen, followed by CBT as treatment for the primary graft rejection 37 days after BMT. The conditioning regimen consisted of fludarabine 25 mg/m 2 once daily i.v. on day À5 to À2 (total dose 100 mg/m 2 ) and BU 0.8 mg/kg four times daily i.v. on day À3 and À2 (total dose 6.4 mg/kg). She received a cord blood infusion containing 2.9 Â 10 7 nucleated cells per kg. CsA was continued for prophylaxis against GVHD. G-CSF was administered from day 1 after CBT. On day 7, she developed fever and skin rash, and liver enzymes became elevated. She was diagnosed as having pre-engraftment immune reaction, which subsided spontaneously without specific treatment in several days. Primary engraftment with neutrophils 40.5 Â 10 9 /l was achieved on day 16, and complete donor chimerism in the bone marrow was confirmed on day 28. A plt count above 20 Â 10 9 /l was observed on day 74. The course of recovery was complicated by bacterial and fungal infection, which responded to antibiotic and antifungal therapies. One year after CBT, the patient remains in CR with chronic extensive GVHD, and follow-up anti-HLA Ab screening with Luminex technology showed no anti-HLA Abs, including the Abs that had existed before transplantation.
Patient 2
A 47-year-old Japanese woman received HLA-mismatched CBT because of early relapse of AML (FAB: M2) in second CR. She had no available HLA-identical donor in her family or from the Japan Marrow Donor Program. Although she had haploidentical children, their HLA Ags were reactive to her anti-HLA Abs. Although she had plt transfusion refractoriness owing to anti-HLA Abs since she received consolidation therapy for AML in first CR 1 year ago, we decided to perform CBT using the aforementioned approach. The preparative regimen consisted of TBI 12 Gy in six fractions from day À7 to À5 and CY 60 mg/kg once daily i.v. on day À4 and À3 (total dose 120 mg/kg). She received serologically two HLA Ag-mismatched cord blood containing 2.1 Â 10 7 nucleated cells per kg. CsA and shortterm MTX were administered for GVHD prophylaxis. She lost consciousness and suffered a seizure because of cerebral infarction due to septic emboli of Bacillus on day 3. Although the sepsis improved with antibiotic therapy, her consciousness disturbance persisted. After that, primary engraftment with neutrophils 40.5 Â 10 9 /l was achieved on day 25. Plt recovery had not been achieved by the time she died of human herpesvirus 6 (HHV6) encephalitis on day 29, which was diagnosed by a positive HHV6 PCR test in post-mortem cerebrospinal fluid.
Allosensitization can be a formidable barrier to hematopoietic stem cell engraftment due to priming of the host's cellular and humoral immune responses. Recent studies showed that the preformed Ab was the major barrier to engraftment in allogeneic SCT. 6 Indeed, a positive crossmatch for the antidonor lymphocytotoxic Ab is associated with graft failure in the clinical setting. 1 Although there have been a few reports on HLA-mismatched SCT for patients with the antidonor lymphocytotoxic Ab, 7,8 the HLA-specific Ab still remains a significant problem in HLA-mismatched SCT, and may be considered as a contraindication in CBT owing to its intrinsic risk of poor engraftment. 2 As Luminex technology has been used to identify acceptable mismatches in highly sensitized patients awaiting kidney transplantation, 4 we applied this approach to two patients with anti-HLA Abs before performing HLA-mismatched CBT. Although patient 2 died of transplant-related complication, patients 1 and 2 received successful engraftment. This procedure may be useful in HLA-mismatched CBT for highly sensitized patients. 
